new independent study

Hey all,

Can't believe no one, nor the share price has picked up this new announcement.

Comments that stand out for me:

“Our work in the yeast model shows that clioquinol decreases the amount of Aß in the cells by 90%. That’s a strong decrease, and it’s dose-dependent. I’ve tested a lot of compounds before, and I’ve never seen anything as dramatic.”

and...

Dr Rudy Tanzi, Professor of Neurology at Harvard Medical School and Prana’s Co-Founder and Chief Scientific Advisor, commented: “this very well crafted body of work from the Lindquist laboratory points to the intrinsic value of Prana’s therapeutic strategy to intercede in the metal mediated toxicity of target aggregating proteins in neurodegeneration.”

“However, unlike strategies which seek to merely reduce Aß levels, our strategy is to additionally dis- arm target proteins of metals, neutralize toxicity, and redistribute metals to their correct neuronal compartments to restore neuronal function and neurotransmission”.

I guess the Aussie market is fully locked and loaded. Let the games begin on NASDAQ.